Division of Cellular Signaling
- Discovery of EML4-ALK fusion tyrosine kinase, ROS1-fusions and RET-fusions
- Cancer genome resequencing with the next-generation sequencers
Lab of Collaborative Research (Masutani Group)
This research group collaborates with the Division of Boron Neutron Capture Therapy of the Exploratory Oncology Research & Clinical Trial Center (NCC-EPOC), the Department of Radiation Oncology, NCC Hospital and other clinical research groups and studies radiation oncology focusing on BNCT and also cancer chemotherapy targeting poly(ADP-ribosylation) and DNA damage response pathways.
- Boron-captured neutron therapy and biological radiosensitization
- The studies of anti-cancer drugs targeting DNA
Lab of Collaborative Research (Shiotani Group)
Human DNA replication requires approximately 3 billion base pairs of DNA to be synthesized accurately in a short period of time, but DNA damage due to external and internal factors and errors associated with DNA replication can not be avoided. Activation of oncogenes and inactivation of tumor suppressor genes in normal cells caused by these factors induces DNA replication stress accompanying abnormal cell proliferation. DNA replication stress promotes further replication error and eventually causes genomic instability. DNA replication stress response mechanism plays a role as a barrier to suppress genomic instability and tumorigenesis, whereas DNA replication stress resistance is required for tumor development. In addition, the DNA replication stress response is a factor showing resistance to DNA-damaging anti-cancer drugs commonly used for cancer chemotherapy. Our group focused on the mechanism of DNA replication stress response that is deeply involved in the process of cancer development and the nature of cancer cells aiming at developing new therapeutic strategies. We are recruiting under graduate, graduate students and research fellows. Please send a CV with past research experience and contact information of three references to:Bunsyo Shiotani, PhD
- Comprehensive identification and functional analysis of specific substrates of ATR, a master regulator of DNA replication stress
- Mechanisms of acquiring genomic instability by DNA replication stress
- Development of cancer therapy targeting DNA replication stress resistance
Lab of Collaborative Research (Masuda Group)
Utilizing innovative cutting-edge genomic and proteomic technologies, our research group is focused on clarifying the molecular and cellular mechanisms of oncogenesis and cancer progression. Aimed at discovering targets of molecular therapy and realizing personalized medicine, comprehensive protein and gene expression profiling of cancer cell lines and cancer tissues has been undertaken. Our current research is directed at the development of a novel Traf2- and Nck-interacting kinase (TNIK) inhibitor selective against colorectal cancer with activation of Wnt signaling which is a key signaling pathway for cancer stem cells (CSCs). In addition, we have applied our in-house reverse-phase protein array (RPPA) platform to the discovery and development of biomarkers for companion diagnostics and precision medicine.